Menarini’s EMERALD study of ORSERDU in breast cancer shows promising results
The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment with new findings from the pivotal EMERALD clinical study. These findings were recently presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). The post hoc analysis of the EMERALD study demonstrated a clinically meaningful improvement in […]